Analysis of Relationship Between Infliximab Treatment Response, Regulatory T Cells, and Interleukin-2 in Crohn's Disease.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 21 Jul 2011 Planned End Date changed from 1 Dec 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 31 Dec 2010 New trial record